In the following video, health care editor/analyst David Williamson discusses the FDA advisory committee vote that sent shares of Arena Pharmaceuticals soaring over 70% in a single day. Obesity drug lorcaserin received an 18-4 recommendation supporting approval. What does this vote mean for Arena's competitors, and is the company poised for monster returns? For a closer look, watch the video and Fool On.
David Williamson holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.